composition as defined herein, for use in the treatment or prophylaxis of transplant rejection or graft-versus-host disease.

Further, there is provided the use of the fusion protein as defined herein for the manufacture of a medicament for the treatment of a disease in an individual in need thereof. In another aspect, there is provided the use of the fusion protein as defined herein for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, wherein the disease is selected from the group consisting of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, transplant rejection and graft-versus-host disease. Further, the disclosure provides a method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the fusion protein as defined herein in a pharmaceutically acceptable form. In one embodiment, said disease is an autoimmune disease. In a more specific embodiment, said autoimmune disease is type 1 diabetes, multiple sclerosis (MS), systemic lupus erythematosus (SLE), inflammatory bowel disease, Crohn's disease or ulcerative colitis. In an even more specific embodiment, said autoimmune disease is type 1 diabetes. In another embodiment said disease is transplant rejection or graft-versus-host disease. In one embodiment, said individual is a mammal, particularly a human.

Further provided is the fusion protein as defined herein for use in selective activation of regulatory T cells *in vitro* or *in vivo*. In another aspect, there is provided the fusion protein as defined herein for use in selective activation of regulatory T cells *in vitro*. In one embodiment, said activation comprises induction of proliferation of regulatory T cells and/or induction of IL-2 receptor signaling, particularly phosphorylation of

29. The fusion protein of any one of claims 1-23, or the pharmaceutical composition of claim 28, for use as a medicament.

30. The fusion protein of any one of claims 1-23, or the pharmaceutical composition of claim 28, for use in the treatment or prophylaxis of an autoimmune disease.

31. The fusion protein or the pharmaceutical composition of claim 30, wherein said autoimmune disease is selected from the group of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis and multiple sclerosis.

32. The fusion protein of any one of claims 1-23, or the pharmaceutical composition of claim 28, for use in the treatment or prophylaxis of transplant rejection or graft-versus-host disease.

33. Use of the fusion protein of any one of claims 1-23 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof, wherein the disease is selected from the group consisting of type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, transplant rejection and graft-versus-host disease.

34. The use of one of claim 33, wherein said individual is a mammal, particularly a human.

35. The fusion protein of any one of claims 1-23 for use in selective activation of regulatory T cells *in vitro*.

36. The fusion protein of claim 35, wherein said activation comprises induction of proliferation of regulatory T cells and/or induction of IL-2 receptor signaling in regulatory T cells.

37. A method for selective activation of regulatory T cells *in vitro*, comprising contacting said regulatory T cells with the fusion protein of any one of claims 1-23.

38. The method of claim 37, wherein said activation comprises induction of proliferation of regulatory T cells and/or induction of IL-2 receptor signaling in regulatory T cells.